SEC-sourced researchBeta
TCRT
Alaunos Therapeutics, Inc.
Company comparison ↗
Data passport
- CIK
- 0001107421
- Exchange
- Nasdaq
- Business activity
- — · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Sep 22, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | No data | Mar 31, 2026 |
| December 2024 | 10,000.0000 | Mar 31, 2026 |
| December 2025 | 5,000.0000 | Mar 31, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 5,000.0000 | -4,176,000.0000 | -2,869,000.0000 | 2,966,000.0000 | 813,000.0000 | Mar 31, 2026 |
| December 2024 | 10,000.0000 | -4,679,000.0000 | -4,971,000.0000 | 2,755,000.0000 | 692,000.0000 | Mar 31, 2026 |
| December 2023 | — | -4,679,000.0000 | — | — | — | Mar 31, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $5K | December 2025 | Mar 31, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $10K | December 2024 | Mar 31, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$4.18M | December 2025 | Mar 31, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$2.87M | December 2025 | Mar 31, 2026 | 10-K |
| Total assetsAssets | $2.97M | December 2025 | Mar 31, 2026 | 10-K |
| Total liabilitiesLiabilities | $813K | December 2025 | Mar 31, 2026 | 10-K |